文献速递肿瘤 PET/CT放射性药物与辐射防护

黑色素靶向PET探针18F-P3BZA的生物分布、辐射剂量学及临床应用

Biodistribution, Radiation Dosimetry, and Clinical Application of a Melanin-Targeted PET Probe, 18F-P3BZA, in Patients.
PubMed 文献 · J Nucl Med · 2018-05-31

本研究在6名健康志愿者中评估18F-P3BZA的生物分布与辐射剂量学,并对5例疑似黑色素瘤患者行18F-P3BZA PET/CT与18F-FDG PET/CT对比。肝脏摄取最高(10分钟SUVmean 8.3±1.0),全身有效剂量0.0193 mSv/MBq;60分钟肿瘤SUVmean 18F-P3BZA 19.7±5.3 vs 18F-FDG 10.8±2.7。研究表明18F-P3BZA安全、兼容临床使用,具有黑色素瘤诊断PET成像潜力。

要点

  • 18F-P3BZA放化产率12.3%±3.9%,纯化后纯度高于99.5%。
  • 肝脏摄取最高,注射后10分钟SUVmean为8.3±1.0。
  • 全身有效剂量为0.0193 mSv/MBq。

核心结论

  • 研究表明18F-P3BZA安全且兼容临床使用,首次人体临床应用在黑色素瘤患者中显示肿瘤勾画良好,展示其用于黑色素瘤诊断PET成像的潜力。

研究设计与样本

  • 研究纳入6名健康志愿者注射18F-P3BZA(211.7±15.4 MBq)后行系列全身PET/CT扫描和血液检查,评估生物分布、药代动力学和辐射剂量学。
  • 采用OLINDA/EXM软件按医学内照射剂量方案计算每名受试者的有效剂量。
  • 初步临床应用纳入5例疑似黑色素瘤患者,注射后10分钟和1小时行18F-P3BZA PET/CT,所有患者第3天行18F-FDG PET/CT以比较诊断能力。

主要发现

  • 18F-P3BZA标记的放化产率为12.3%±3.9%,纯化与配制后纯度高于99.5%。
  • 注射后10分钟肝脏摄取最高,SUVmean为8.3±1.0。
  • 全身有效剂量为0.0193 mSv/MBq。
  • 注射后60分钟肿瘤平均SUVmean:18F-P3BZA为19.7±5.3,18F-FDG为10.8±2.7。
  • 18F-P3BZA在患者中显示高摄取,并提示具备对黑色素瘤及其转移灶进行特异性成像的能力。

关键数值与推荐

  • 健康志愿者注射18F-P3BZA剂量为211.7±15.4 MBq。
  • PET/CT扫描时间点为注射后10分钟、1小时、2小时和4小时。
  • 疑似黑色素瘤患者行18F-P3BZA PET/CT的时间点为注射后10分钟和1小时,18F-FDG PET/CT在第3天进行。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

N-(2-(diethylamino)-ethyl)-18F-5-fluoropicolinamide (18F-P3BZA) is a radiotracer that demonstrates high binding selectivity and affinity in melanoma. The aim of the present study was to estimate the biodistribution and clinical radiation dosimetry of 18F-P3BZA in healthy volunteers and perform a preliminary clinical application for PET/CT imaging in melanoma patients. Methods:18F-P3BZA was produced efficiently with a radiosynthesizer. Six healthy volunteers were injected with 18F-P3BZA (211.7 ± 15.4 MBq) followed by serial whole-body PET/CT scans and blood tests to assess biodistribution, pharmacokinetic, and radiation dosimetry at 10 min, 1 h, 2 h, and 4 h after injection. The vital signs of volunteers were recorded in regular intervals during the imaging sessions. The effective dose for each subject after the medical internal radiation dosimetry schema was calculated with OLINDA/EXM software. For the preliminary clinical application, 5 patients with suspected melanomas underwent 18F-P3BZA PET/CT imaging at 10 min and 1 h after injection. All patients also underwent 18F-FDG PET/CT scans on the third day to compare the potential diagnostic ability of 18F-P3BZA with 18F-FDG. Results: The radiochemistry yield of 18F-P3BZA labeling was 12.3% ± 3.9%, and the purity of 18F-P3BZA after purification and formulation was higher than 99.5%. The highest uptake of 18F-P3BZA was in the liver with an SUVmean of 8.3 ± 1.0 at 10 min after injection. The resultant whole-body effective dose was 0.0193 mSv/MBq. 18F-P3BZA showed high uptake and suggested an ability for specific imaging of melanoma and its metastasis in patients. The average SUVmean of 18F-P3BZA and 18F-FDG in tumors was 19.7 ± 5.3 and 10.8 ± 2.7 at 60 min after injection. Conclusion: Our study suggests that 18F-P3BZA is safe and compatible for clinical use. The first-in-human clinical application to melanoma showed favorable delineated tumors in patients, demonstrating the potential of 18F-P3BZA for diagnostic PET imaging of melanoma.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Ma X, Wang S, Wang S, et al. Biodistribution, Radiation Dosimetry, and Clinical Application of a Melanin-Targeted PET Probe, 18F-P3BZA, in Patients. J Nucl Med. 2018. PMID: 29853651. doi:10.2967/jnumed.118.209643

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。